Icotinib Versus Vinorelbine/Platinum as Adjuvant Therapy in Stage II-IIIA Non-small Cell Lung Cancer With EGFR-mutation

Mise à jour : Il y a 4 ans
Référence : NCT02448797

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Adjuvant therapy has been proved effective in treating earlier stage or less advanced non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating stage II-IIIA non-small cell lung cancer patients with EGFR mutation. The primary endpoint is disease-free survival.


Critère d'inclusion

  • non-small cell lung cancer

Liens